Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer

A meta-analysis compared disease-free survival among patients with HR+ HER2- breast cancer who received adjuvant endocrine therapy with tamoxifen or an aromatase inhibitor. The results demonstrated a significant improvement in disease-free survival among patients who received an aromatase inhibitor versus those who received tamoxifen. This difference was more pronounced in patients who were premenopausal.